FMP

FMP

Enter

CYAD - Celyad Oncology SA

Financial Summary of Celyad Oncology SA(CYAD), Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and develop

photo-url-https://financialmodelingprep.com/image-stock/CYAD.png

Celyad Oncology SA

CYAD

NASDAQ

Inactive Equity

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company's preclinical candidate includes CYAD-203, a non-gene edited allogeneic CAR-T candidate to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for the treatment of solid tumors. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.

0.47 USD

-0.07 (-14.89%)

About

ceo

Dr. Georges Rawadi

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company's precl...

CIK

0001637890

ISIN

US1512052002

CUSIP

151205200

Address

Axis Business Park

Phone

32 1 039 41 00

Country

BE

Employee

35

IPO Date

Jun 19, 2015

Summary

CIK

0001637890

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

151205200

ISIN

US1512052002

Country

BE

Price

0.47

Beta

1.69

Volume Avg.

18.06k

Market Cap

14.24M

Shares

-

52-Week

0.15-3.07

DCF

1.95

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-0.32

P/B

-

Website

https://www.celyad.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest CYAD News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep